

# Clinical trials of antithrombotics for percutaneous coronary intervention in all type of patients

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 antiplatelet drugs

Trial	Treatments	Patients	Trials design and methods
<b>vs placebo</b>			
<b>Finci , 1989</b> n=54/53 follow-up: 6m	-	-	Parallel groups
<b>Oriol , 1995</b> n=171/171 follow-up: 6m	-	-	Parallel groups
<b>aspirin vs placebo</b>			
<b>Taylor (Perth) , 1991</b> n=124/128 follow-up: 6m	aspirin, 100 mg/day after 2 weeks versus placebo	patients aged less than 70 years without acute infarction undergoing PTCA	Parallel groups double blind
<b>M-HEART II (aspirin) , 1995</b> n=497/510 follow-up: 6m	aspirin 325 mg daily versus placebo	patients undergoing PTCA	Parallel groups double blind
<b>aspirin + dipyridamol vs placebo</b>			
<b>Schwartz (Toronto) , 1988</b> n=187/189 follow-up: 6m	aspirin 990 + D225 (H) versus placebo	-	Parallel groups double blind Canada
<b>White (aspirin+dipiridamol) , 1991</b> n=245/254 follow-up: 6m	-	-	Parallel groups
<b>Nye (Dunedin) , 1990</b> n=35/37 follow-up: 12m	aspirin 300 + D225 versus placebo	-	Parallel groups NA
<b>Mayo-PTCA , 1989</b> n=102/105 follow-up: 48h	-	-	Parallel groups
<b>sulotroban vs placebo</b>			
<b>M-HEART II (sulotroban) , 1995</b> n=752 follow-up: 6 months	-	patients undergoing PTCA	Parallel groups double blind
<b>ticlopidine vs placebo</b>			

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>White (ticlopidine) , 1991</b> n=NA follow-up: 6m	ticlopidine 500, aspirin 650 + D225 versus placebo	-	Parallel groups
<b>TACT , 1990</b> n=177/173 follow-up: 6m	-	-	Parallel groups

## References

### **Finci, 1989:**

Finci L, Hfling B, Ludwig B, Bulitta M, Steffino G, Etti H, et al. Sulotroban during and after coronary angioplasty. A double-blind placebo controlled study Zeitschrift fr Kardiologie 1989;78(suppl 3):50-4

### **Oriol, 1995:**

Oriol A. Multicentre, double-blind study of triflusal in comparison to placebo in patients after percutaneous transluminal coronary angioplasty/x Barcelona, Spain: J. Uriach & Ca., S.A., 1995:(Internal report TRII-90/IV- 04)

### **Taylor (Perth), 1991:**

Taylor RR, Gibbons FA, Cope GD, Cumpston GN, Mews GC, Luke P Effects of low-dose aspirin on restenosis after coronary angioplasty. Am J Cardiol 1991;68:874-8 [[1927946](#)]

### **M-HEART II (aspirin), 1995:**

Savage MP, Goldberg S, Bove AA, Deutsch E, Vetrovec G, Macdonald RG, Bass T, Margolis JR, Whitworth HB, Taussig A Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II) Circulation 1995;92:3194-200 [[7586303](#)]

### **Schwartz (Toronto), 1988:**

Schwartz L, Bourassa MG, Lesprance J, Aldridge HE, Kazim F, Salvatori VA, Henderson M, Bonan R, David PR Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988;318:1714-9 [[2967433](#)]

### **White (aspirin+dipiridamol), 1991:**

White CW, Chaitman B, Knudtson ML, Chisholm RJ, and the Ticlopidine Study Group. Antiplatelet agents are effective in reducing the acute ischemic complications of angioplasty but do not prevent restenosis: results from the ticlopidine trial Coronary Artery Dis 1991;2:757-67

### **Nye (Dunedin), 1990:**

Nye ER, Ablett MB, Robertson MC, Ilsley CD, Sutherland WH Effect of eicosapentaenoic acid on restenosis rate, clinical course and blood lipids in patients after percutaneous transluminal coronary angioplasty. Aust N Z J Med 1990;20:549-52 [[2222347](#)]

### **Mayo-PTCA, 1989:**

Chesebro JH, Webster MW, Reeder GS, Mock MB, Grill DE, Bailey KR, et al. Coronary angioplasty: antiplatelet therapy reduces acute complications but not restenosis Circulation 1989;80 (suppl II):II-64 (Abstract 0257)

### **M-HEART II (sulotroban), 1995:**

Savage MP, Goldberg S, Bove AA, Deutsch E, Vetrovec G, Macdonald RG, Bass T, Margolis JR, Whitworth HB, Taussig A Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II) Circulation 1995 Dec 1;92:3194-200 [[7586303](#)]

### **White (ticlopidine), 1991:**

### **TACT, 1990:**

Bertrand ME, Allain H, LaBlanche JM, on behalf of Investigators of the TACT Study Results of a randomized trial of ticlopidine versus placebo for prevention of acute closure and restenosis after coronary angioplasty (PTCA): the TACT study Circulation 1990;82(suppl III):190 (Abstract 0754)

## 2 competitive PAR-1 antagonist

Trial	Treatments	Patients	Trials design and methods
<b>SCH 530348 vs placebo</b>			
TRA-PCI , 2009 [NCT00132912] n=NA follow-up:	SCH 530348 3 doses: 10mg, 20mg and 40mg versus placebo	patients aged 45 years or older and undergoing non-urgent PCI or coronary angiography with planned PCI	Parallel groups double-blind

## References

### TRA-PCI, 2009:

Becker RC, Moliterno DJ, Jennings LK, Pieper KS, Pei J, Niederman A, Ziada KM, Berman G, Strony J, Joseph D, Mahaffey KW, Van de Werf F, Veltri E, Harrington RA Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009 Mar 14;373:919-28 [19286091] [10.1016/S0140-6736\(09\)60230-0](https://doi.org/10.1016/S0140-6736(09)60230-0)

## 3 direct thrombin inhibitor

Trial	Treatments	Patients	Trials design and methods
<b>bivalirudin vs heparin + GP2b3a inhibitors</b>			
ACUTY (Stone) (bivalirudin alone) , 2006 [NCT00093158] n=9216/4603 follow-up: 30 days	bivalirudin alone versus unfractionated heparin or enoxaparin plus a glycoprotein IIb/IIIa inhibitor	patients with acute coronary syndromes	Parallel groups open
HORIZONS-AMI (Stone) , 2008 [NCT00433966] n=1800/1802 follow-up: 30 days	Bivalirudin versus Heparin plus GP IIb/IIIa inhibitor	patients with ST-segment elevation myocardial infarction who presented within 12 hours after the onset of symptoms and who were undergoing primary PCI	Parallel groups open 11 countries
REPLACE-2 , 2003 n=2994/3008 follow-up: 30 days	bivalirudin, with glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibition on a provisional basis for complications during PCI versus heparin plus planned Gp IIb/IIIa blockade	patients undergoing urgent or elective PCI	Parallel groups double blind 9 countries
<b>bivalirudin + eptifibatide vs heparin + GP2b3a inhibitors</b>			
Kleiman , 2002 n=NA follow-up:	bivalirudin + eptifibatide versus heparin + eptifibatide	patients who underwent elective percutaneous coronary intervention	Parallel groups open
<b>bivalirudin vs UFH</b>			

continued...

Trial	Treatments	Patients	Trials design and methods
<b>ARMYDA BIVALVE</b> n=140 follow-up:	bivalirudin (0.75 mg/kg bolus followed by 1.75 mg/kg per hour during the procedure) versus unfractionated heparin (75 IU/kg)	patients at high bleeding risk (over 75 years of age, diabetes, reduced renal function) scheduled for PCI	Parallel groups
<b>BAT (Bittl) , 1995</b> n=2059/2039 follow-up: hospital stay	bivalirudin immediately before angioplasty. versus heparin immediately before angioplasty	patients undergoing urgent angioplasty for unstable or postinfarction angina	Parallel groups double blind US
<b>ISAR-REACT 3 , 2008</b> [NCT00262054] n=2289/2281 follow-up: 30 days (mean)	UFH bolus of 140 U/kg versus bivalirudin (bolus of 0.75 mg/kg, followed by infusion of 1.75 mg/kg/hr)	troponin-negative patients undergoing PCI	Parallel groups double blind
<b>REPLACE-1 , 2004</b> n=532/524 follow-up: hospital stay (48h min)	bivalirudin (0.75 mg/kg bolus, 1.75 mg/kg/h infusion during the procedure) versus heparin (70 U/kg initial bolus) adjusted to ACT of 200 to 300s	patients undergoing elective or urgent revascularization	Parallel groups US
<b>bivalirudin vs UFH plus tirofiban</b>			
<b>NAPLES (Tavano) , 2009</b> n=167/168 follow-up: 30 days	bivalirudin monotherapy versus unfractionated heparin plus tirofiban	patients with diabetes mellitus undergoing elective percutaneous coronary intervention	Parallel groups open Italy

4

## References

### ACUITY (Stone) (bivalirudin alone), 2006:

Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM, , Bivalirudin for patients with acute coronary syndromes. *N Engl J Med* 2006;355:2203-16. [17124018] [10.1056/NEJMoa062437](https://doi.org/10.1056/NEJMoa062437)

### HORIZONS-AMI (Stone), 2008:

Mehran R, Brodie B, Cox DA, Grines CL, Rutherford B, Bhatt DL, Dangas G, Feit F, Ohman EM, Parise H, Fahy M, Lansky AJ, Stone GW, The Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. *Am Heart J* 2008;156:44-56. [18585496] [10.1016/j.ahj.2008.02.008](https://doi.org/10.1016/j.ahj.2008.02.008)

Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R Bivalirudin during primary PCI in acute myocardial infarction. *N Engl J Med* 2008 May 22;358:2218-30 [18499566]

Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Fahy M, Parise H, Mehran R Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. *Lancet* 2011 Jun 25;377:2193-2204 [21665265] [10.1016/S0140-6736\(11\)60764-2](https://doi.org/10.1016/S0140-6736(11)60764-2)

### REPLACE-2, 2003:

Gibson CM, Ten Y, Murphy SA, Ciaglo LN, Southard MC, Lincoff AM, Waksman R, Association of prerandomization anticoagulant switching with bleeding in the setting of percutaneous coronary intervention (A REPLACE-2 analysis). *Am J Cardiol* 2007;99:1687-90. [17560876] [10.1016/j.amjcard.2007.01.053](https://doi.org/10.1016/j.amjcard.2007.01.053)

Cohen DJ, Lincoff AM, Lavelle TA, Chen HL, Bakhai A, Berezin RH, Jackman D, Sarembock IJ, Topol EJ, Economic evaluation of bivalirudin with provisional glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. *J Am Coll Cardiol* 2004;44:1792-800. [15519009] [10.1016/j.jacc.2004.05.085](https://doi.org/10.1016/j.jacc.2004.05.085)

Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ, , Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004;292:696-703. [15304466] [10.1001/jama.292.6.696](https://doi.org/10.1001/jama.292.6.696)

Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003 Feb 19;289:853-63 [12588269]

**Kleiman, 2002:**

Kleiman NS, Klem J, Fernandes LS, Rubin H, Challa S, Solomon S, Maresh K, Arora U, Klem E, Buegler J, Mathew S, Browning A, DeLao T, Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. Am Heart J 2002;143:585-93. [11923794]

**ARMYDA BIVALVE, :**

**BAT (Bittl), 1995:**

Bittl JA, Feit F, A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina. Hirulog Angioplasty Study Investigators. Am J Cardiol 1998;82:43P-49P. [9809891]

Shah PB, Ahmed WH, Ganz P, Bittl JA, Bivalirudin compared with heparin during coronary angioplasty for thrombus-containing lesions. J Am Coll Cardiol 1997;30:1264-9. [9350925]

Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, Maraganore J, Deutsch E, Adelman B, Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 1995;333:764-9. [7643883]

Bittl JA, Comparative safety profiles of hirulog and heparin in patients undergoing coronary angioplasty. The Hirulog Angioplasty Study Investigators. Am Heart J 1995;130:658-65. [7668214]

Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001;142:952-9 [11717596]

**ISAR-REACT 3, 2008:**

Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Bttner HJ, Khattab AA, Schulz S, Blankenship JC, Pache J, Minners J, Seyfarth M, Graf I, Skelding KA, Dirschinger J, Richardt G, Berger PB, Schmig A Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention. N Engl J Med 2008 Aug 14;359:688-696 [18703471]

**REPLACE-1, 2004:**

Lincoff AM, Bittl JA, Kleiman NS, Sarembock IJ, Jackman JD, Mehta S, Tannenbaum MA, Niederman AL, Bachinsky WB, Tift-Mann J, Parker HG, Kereiakes DJ, Harrington RA, Feit F, Maieron ES, Chew DP, Topol EJ, , Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol 2004;93:1092-6. [15110198] [10.1016/j.amjcard.2004.01.033](https://doi.org/10.1016/j.amjcard.2004.01.033)

**NAPLES (Tavano), 2009:**

Tavano D, Visconti G, D'Andrea D, Focaccio A, Golia B, Librera M, Caccavale M, Ricciarelli B, Briguori C Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention. Am J Cardiol 2009;104:1222-8 [19840566]

## 4 fondaparinux

Trial	Treatments	Patients	Trials design and methods
<b>fondaparinux vs unfractionated heparin or bivalirudin</b>			
<b>SWITCH III</b> <i>ongoing</i> [NCT00464087] n=NA follow-up:	fondaparinux versus unfractionated heparin or bivalirudin	patients experiencing acute coronary syndrome undergoing percutaneous coronary angioplasty	Parallel groups open

## References

SWITCH III, :

### 5 GP IIaIIIb inhibitors

Trial	Treatments	Patients	Trials design and methods
<b>vs</b>			
IMPACT (12h) , 1993 n=NA	-	-	
EPIC (without infusion) , 1991 n=NA	-	-	
IMPACT-II (0.75g) , 1994 n=NA	-	-	
<b>Abciximab vs placebo</b>			
ADMIRAL , 2001 n=NA	-	Primary PCI	
CADILLAC , 2002 n=NA	-	Primary PCI	
RAPPORT , 1998 n=NA	-	Primary PTCA <	
EPIC (with infusion) , 1994 n=NA	-	High risk for abrupt closurebitm	
EPILOG , 1997 n=NA	-	Elective or urgent PCIe	
EPISTENT , 1998 n=NA	-	Elective or urgent PCI	
CAPTURE , 1997 n=NA	-	-	
ERASER , 1999 n=NA	-	-	
Petronio , 2002 n=NA	-	-	
Simoons , 1994 n=NA	-	-	
Kini , 2001 n=NA	-	-	
Tamburino , 2002 n=NA	-	-	
ISAR-2 , 2000 n=NA	-	PCI <48 h after MI	
<b>Eptifibatide vs placebo</b>			

continued...

Trial	Treatments	Patients	Trials design and methods
ESPRIT , 2000 n=NA	-	Nonurgent PCI	
IMPACT (4h) , 1995 n=NA	-	Elective PCI	
IMPACT-II (0.5g) , 1997 n=NA	-	Any PCI	
Harrington , 1995 n=NA	-	-	
<b>Tirofiban vs placebo</b>			
RESTORE , 1997 n=NA	-	PCI <72 h after USA or MI	
Kereiakis , 1996 n=NA	-	-	

## References

### IMPACT (12h), 1993:

### EPIC (without infusion), 1991:

### IMPACT-II (0.75g), 1994:

### ADMIRAL, 2001:

Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, Boulenc JM, Morice MC, Maillard L, Pansiri M, Choussat R, Pinton P Platelet glycoprotein Iib/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-903 [[11419426](#)]

### CADILLAC, 2002:

Stone GW, Grines CL, Cox DA, Garcia E, Tchong JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-66 [[11919304](#)]

### RAPPORT, 1998:

Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, Cohen ED, Gainey PC, White HJ, Cheek HB, Moses JW, Moliterno DJ, Effron MB, Topol EJ Randomized, placebo-controlled trial of platelet glycoprotein Iib/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998;98:734-41 [[9727542](#)]

### EPIC (with infusion), 1994:

Use of a monoclonal antibody directed against the platelet glycoprotein Iib/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330:956-61 [[8121459](#)]

Topol EJ, Califf RM, Weisman HF, Ellis SG, Tchong JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M Randomised trial of coronary intervention with antibody against platelet Iib/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 1994;343:881-6 [[7908357](#)]

Topol EJ, Ferguson JJ, Weisman HF, Tchong JE, Ellis SG, Kleiman NS, Ivanhoe RJ, Wang AL, Miller DP, Anderson KM, Califf RM Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet Iib/IIIa Inhibition for Prevention of Ischemic Complication. JAMA 1997;278:479-84 [[9256222](#)]

### EPILOG, 1997:

Platelet glycoprotein Iib/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997;336:1689-96 [[9182212](#)]

### EPISTENT, 1998:

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. *Lancet* 1998;352:87-92 [9672272]

Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, Kleiman NS, Cohen EA, Booth JE, Sapp SK, Cabot CF, Topol EJ Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. *N Engl J Med* 1999;341:319-27 [10423466]

Topol EJ, Mark DB, Lincoff AM, Cohen E, Burton J, Kleiman N, Talley D, Sapp S, Booth J, Cabot CF, Anderson KM, Califf RM Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. *Lancet* 1999;354:2019-24 [10636365]

#### **CAPTURE, 1997:**

Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. *Lancet* 1997;349:1429-35 [9164316]

#### **ERASER, 1999:**

Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). The ERASER Investigators. *Circulation* 1999;100:799-806 [10458714]

#### **Petronio, 2002:**

Petronio AS, Musumeci G, Limbruno U, De Carlo M, Baglini R, Paterni G, Grazia Delle Donne M, Caravelli P, Nardi C, Mariani M Abciximab improves 6-month clinical outcome after rescue coronary angioplasty. *Am Heart J* 2002;143:334-41 [11835040]

#### **Simoons, 1994:**

Simoons ML, de Boer MJ, van den Brand MJ, van Miltenburg AJ, Hoorntje JC, Heyndrickx GR, van der Wieken LR, de Bono D, Rutsch W, Schaible TF Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group. *Circulation* 1994;89:596-603 [7508826]

#### **Kini, 2001:**

Kini A, Reich D, Marmur JD, Mitre CA, Sharma SK Reduction in periprocedural enzyme elevation by abciximab after rotational atherectomy of type B2 lesions: Results of the Rota ReoPro randomized trial. *Am Heart J* 2001;142:965-9 [11717598]

#### **Tamburino, 2002:**

Tamburino C, Russo G, Nicosia A, Galassi AR, Foti R, Scriffignano V, Kereiakes DJ, Giuffrida G Prophylactic abciximab in elective coronary stenting: results of a randomized trial. *J Invasive Cardiol* 2002;14:72-9 [11818641]

#### **ISAR-2, 2000:**

Neumann FJ, Kastrati A, Schmitt C, Blasini R, Hadamitzky M, Mehilli J, Gawaz M, Schleaf M, Seyfarth M, Dirschinger J, Schmig A Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. *J Am Coll Cardiol* 2000;35:915-21 [10732888]

#### **ESPRIT, 2000:**

Novel dosing regimen of eptifibatid in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. *Lancet* 2000;356:2037-44 [11145489]

#### **IMPACT (4h), 1995:**

Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FI, Smith JE, Worley SJ Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. *Circulation* 1995;91:2151-7 [7697843]

#### **IMPACT-II (0.5g), 1997:**

Randomised placebo-controlled trial of effect of eptifibatid on complications of percutaneous coronary intervention: IMPACT-II. Integrelin to Minimise Platelet Aggregation and Coronary Thrombosis-II. *Lancet* 1997;349:1422-8 [9164315]

#### **Harrington, 1995:**

Harrington RA, Kleiman NS, Kottke-Marchant K, Lincoff AM, Tcheng JE, Sigmon KN, Joseph D, Rios G, Trainor K, Rose D Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. *Am J Cardiol* 1995;76:1222-7 [7503000]

#### **RESTORE, 1997:**



Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. *Circulation* 1997;96:1445-53 [9315530]

Gibson CM, Goel M, Cohen DJ, Piana RN, Deckelbaum LI, Harris KE, King SB 3rd Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. *J Am Coll Cardiol* 1998;32:28-34 [9669245]  
**Kereiakis, 1996:**

Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T, Herrmann HC, Sutton JM, Weaver WD, McKee DB, Fitzpatrick V, Sax FL Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. *J Am Coll Cardiol* 1996;27:536-42 [8606262]

## 6 Low Molecular Weight Heparin

Trial	Treatments	Patients	Trials design and methods
<b>dalteparin vs UFH</b>			
Natarajan (without antiGp2b3a) , 2003 n=NA follow-up:	Dalteparin 100 IU/kg bolus versus UFH 100 IU/kg bolus	Elective or urgent PCI	
<b>enoxaparin vs UFH</b>			
ATOLL , 2010 n=450/460 follow-up: 30 days	IV enoxaparin versus UFH	patients undergoing PCI for acute STEMI	Parallel groups open Austria, France, Germany, and US
Brieger n=346/234 follow-up:	enoxaparin versus unfractionated heparin	patients undergoing percutaneous coronary intervention for ST-segment elevation myocardial infarction (STEMI)	
CRUISE , 2003 n=129/132 follow-up: 2,7 +30 days	Enoxaparin 0.75 mg/kg bolus versus 65279;UFH 60 IU/kg bolus, then titrated to ACT >200	Urgent or elective PCI	Parallel groups open
Drozd , 2001 n=50/50 follow-up: 24hrs, 30 days	65279;Enoxaparin 1 mg/kg bolus versus UFH 100 IU/kg bolus	PCI for stable angina	
Dudek , 2000 n=200/200 follow-up: 3 days	Enoxaparin 1 mg/kg bolus versus UFH titrated to ACT >300	PCI	
Dudek b (enox alone) , 2000 n=NA follow-up:	Enoxaparin 1 mg/kg bolus versus UFH titrated to ACT >300	PTCA complex lesionsCI	
Galeote , 2001 n=50/49 follow-up:	Enoxaparin 0.75 mg/kg bolus versus UFH 70 U/kg bolus, then titrated to ACT >200	PTCA patients with stable/unstable angina or AMI	

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>Rabah , 1999</b> n=30/30 follow-up:	Enoxaparin 1 mg/kg bolus versus 65279;UFH 10,000 IU bolus, then titrated to ACT >300	PCI for stable angina	Parallel groups open
<b>STEEPLE , 2006</b> [NCT00077844] n=NA follow-up:	enoxaparin (0.5 or 0.75 mg per kilogram of body weight) versus unfractionated heparin (adjusted for activated clotting time)	elective percutaneous coronary intervention.	Parallel groups open
<b>enoxaparin+abciximab vs UFH</b>			
<b>Dubek b (+abciximal) , 2001</b> n=NA	Enoxaparin 0.75 mg/kg bolus + abciximab versus UFH titrated to ACT >300	-	
<b>reviparin vs UFH</b>			
<b>REDUCE , 1996</b> n=306/306 follow-up: 3 days	65279;Reviparin 7,000 IU anti-Xa versus UFH 10,000 IU bolus	PTCA with stable/unstable angina	Parallel groups double blind Europe and Canada
<b>dalteparin vs UFH + anti Gp2b3a</b>			
<b>Natarajan (+ antiGp2b3a) , 2003</b> n=NA	Dalteparin 70 IU/kg bolus + GP IIb/IIIa inhibitorse/p versus 65279;UFH 70 IU/kg bolus +GPIIb/IIIa inhibitors	-	
<b>enoxaparin vs unfractionated heparin</b>			
<b>STREAM ongoing</b> [NCT00882635] n=NA follow-up:	Enoxaparin versus Unfractionated Heparin	St Elevation Myocardial Infarction patients undergoing primary percutaneous coronary intervention	

## References

### **Natarajan (without antiGp2b3a), 2003:**

NatarajanMK, Turpie GA, Raco DL, Velianon JL,Mehta SR, Afzal A randomized comparison of dalteparin versus unfractionated heparin during percutaneous coronary interventions. J Am Coll Cardiol 2003;41(Suppl A):68A69A.xtPag

### **ATOLL, 2010:**

#### **Brieger, :**

Brieger D, Collet JP, Silvain J, Landivier A, Barthlmy O, Beygui F, Bellemain-Appaix A, Mercadier A, Choussat R, Vignolles N, Costagliola D, Montalescot G Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention. Catheter Cardiovasc Interv 2011;77:182-90 [20578166] [10.1002/ccd.22674](https://doi.org/10.1002/ccd.22674)

### **CRUISE, 2003:**

Bhatt DL, Lee BI, Casterella PJ, Pulsipher M, Rogers M, Cohen M, Corrigan VE, Ryan TJ Jr, Breall JA, Moses JW, Eaton GM, Sklar MA, Lincoff AM Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. J Am Coll Cardiol 2003;41:20-5 [12570939]

### **Drozd, 2001:**

Drozd J, Opalinska E, Wojcik J, Madejczyk A. Pag The use of enoxaparin during percutaneous coronary angioplasty in patients with stable angina Kardiol Pol 2001;55:520524

**Dudek, 2000:**

Dudek D, Dabrowski M, Ochala A, Lesaik M, Wnek A, Bryniarski Multicenter, prospective, double-blind randomized comparison of enoxaparin versus unfractionated heparin for percutaneous coronary interventions Am J Cardiol 2000;86(Suppl 8A):15i. imag

**Dudek b (enox alone), 2000:**

Dudek D, Bartus S, Zymek P, Legutko J, Rzeszutko L, Janion M, Abciximab and enoxaparin administration during elective high-risk PTCA in patients with more than 3 days of ticlopidine pretreatment. J Am Coll Cardiol 2000;35(Suppl):91A

**Galeote, 2001:**

Galeote G, Hussein M, Sobrino N, Calvo L, Yunda H, Sanchez- Combination abciximab and enoxaparin or unfractionated heparin during percutaneous coronary intervention: a randomised study Eur Heart J 2001;22(Suppl):663

**Rabah, 1999:**

Rabah MM, Premmereur J, Graham M, Fareed J, Hoppensteadt DA, Grines LL, Grines CL Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999;84:1391-5 [10606110]

**STEEPLE, 2006:**

Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, Bode C, Chiariello M, King SB 3rd, Harrington RA, Desmet WJ, Macaya C, Steinhubl SR Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006;355:1006-17 [16957147]

**Dubek b (+abciximal), 2001:**

**REDUCE, 1996:**

Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation. J Am Coll Cardiol 1996;28:1437-43 [8917255]

**Natarajan (+ antiGp2b3a), 2003:**

**STREAM, :**

## 7 P2Y12 receptor antagonist

Trial	Treatments	Patients	Trials design and methods
<b>elinogrel vs clopidogrel</b>			
<b>INNOVATE PCI</b> [NCT00751231] n=NA follow-up:	-	-	

## References

**INNOVATE PCI, :**

Welsh RC, Rao SV, Zeymer U, Thompson VP, Huber K, Kochman J, McClure MW, Gretler DD, Bhatt DL, Gibson CM, Angiolillo DJ, Gurbel PA, Berdan LG, Paynter G, Leonardi S, Madan M, French WJ, Harrington RA A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Circ Cardiovasc Interv 2012;5:336-46 [22647518]

Angiolillo DJ, Welsh RC, Trenk D, Neumann FJ, Conley PB, McClure MW, Stephens G, Kochman J, Jennings LK, Gurbel PA, Wjck J, Dabrowski M, Saucedo JF, Stumpf J, Buerke M, Broderick S, Harrington RA, Rao SV Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. *Circ Cardiovasc Interv* 2012;5:347-56 [22619259]

Welsh RC, Rao SV, Zeymer U, Thompson VP, Huber K, Kochman J, McClure MW, Gretler DD, Bhatt DL, Gibson CM, Angiolillo DJ, Gurbel PA, Berdan LG, Paynter G, Leonardi S, Madan M, French WJ, Harrington RA A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. *Circ Cardiovasc Interv* 2012;5:336-46 [22647518]

## 8 reversible ADP receptor antagonist

Trial	Treatments	Patients	Trials design and methods
<b>cangrelor vs clopidogrel</b>			
<b>CHAMPION PHOENIX , 2013</b> [NCT01156571] n=5472/5470 follow-up: 48 hours	bolus and infusion of cangrelor followed by 600mg clopidogrel immediately post-infusion versus loading dose of 600 mg or 300 mg of clopidogrel	patients undergoing PCI for stable angina or for acute coronary syndromes, including ST-elevation MI	Parallel groups double-blind
<b>cangrelor up front vs clopidogrel up front</b>			
<b>CHAMPION-PCI , 2009</b> [NCT00305162] n=4367/4355 follow-up: 48 h	cangrelor up front (cangrelor administered before percutaneous coronary intervention and followed by clopidogrel) versus clopidogrel up front (clopidogrel followed by placebo)	high risk patients requiring PCI	Parallel groups double blind 14 countries
<b>cangrelor up front vs delayed clopidogrel</b>			
<b>CHAMPION-PLATFORM , 2009</b> [NCT00385138] n=2693/2669 follow-up: 48 h	cangrelor up front (cangrelor during PCI followed by 600 mg of clopidogrel) versus delayed clopidogrel (placebo during PCI followed by 600 mg of clopidogrel)	patients with acute coronary syndrome undergoing percutaneous coronary intervention	Parallel groups double blind 18 countries

## References

### CHAMPION PHOENIX, 2013:

Leonardi S, Mahaffey KW, White HD, Gibson CM, Stone GW, Steg GW, Hamm CW, Price MJ, Todd M, Dietrich M, Gallup D, Liu T, Skerjanec S, Harrington RA, Bhatt DL Rationale and design of the Cangrelor versus standard therapy to achieve optimal Management of Platelet InhibitiON PHOENIX trial. *Am Heart J* 2012;163:768-776.e2 [22607853]

Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimsk P, Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo DJ, Gneux P, Liu T, Prats J, Todd M, Skerjanec S, White HD, Harrington Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. *N Engl J Med* 2013 Mar 10;: [23473369] 10.1056/NEJMoa1300815

### CHAMPION-PCI, 2009:

Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, Pollack CV Jr, Montalescot G, Mahaffey KW, Kleiman NS, Goodman SG, Amine M, Angiolillo DJ, Becker RC, Chew DP, French WJ, Leisch F, Parikh KH, Skerjanec S, Bhatt DL Platelet inhibition with cangrelor in patients undergoing PCI. *N Engl J Med* 2009 Dec 10;361:2318-29

[19915221]

### CHAMPION-PLATFORM, 2009:

Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV Jr, Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, Skerjanec S, Harrington RA Intravenous Platelet Blockade with Cangrelor during PCI. N Engl J Med 2009 Nov 15; [19915222]

## 9 thienopyridine

Trial	Treatments	Patients	Trials design and methods
<b>prasugrel vs clopidogrel</b>			
<b>TRITOM TIMI 38 (PCI subgroup) , 2009</b> n=1769/1765 follow-up:	prasugrel (60 mg loading, 10 mg maintenance) versus clopidogrel (300 mg loading, 75 mg maintenance)	subgroup of patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction	
<b>JUMBO-TIMI 26 , 2005</b> n=650/254 follow-up: 30 days	Prasugrel 3 doses versus clopidogrel 300mg loading dose followed by 75 mg daily)	patients undergoing elective or urgent percutaneous coronary intervention	Parallel groups double blind
<b>TRIGGER-PCI</b> <i>ongoing</i> [NCT00910299] n=NA follow-up: 6 months	prasugrel one time 60-mg oral loading dose and 10-mg once daily oral maintenance dose up to 6 months versus clopidogrel 75-mg oral daily maintenance dose up to 6 months	patients With High Platelet Reactivity on Clopidogrel Following Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stent	Parallel groups double blind
<b>Prasugrel and Bivalirudin vs Clopidogrel and Heparin</b>			
<b>BRAVE-4</b> <i>ongoing</i> [NCT00976092] n=NA follow-up:	Prasugrel + Bivalirudin versus Clopidogrel + Heparin	STEMI patients undergoing PPCI	

## References

### TRITOM TIMI 38 (PCI subgroup), 2009:

Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009;373:723-31 [19249633] 10.1016/S0140-6736(09)60441-4

### JUMBO-TIMI 26, 2005:

Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005 Jun 28;111:3366-73 [15967851]

### TRIGGER-PCI, :

### BRAVE-4, :

## 10 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.